Europe Coagulation Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

Analysis - by Disease Indications (Vitamin K Deficiency, Liver Disease, Disseminated Intravascular Coagulation & Pulmonary Embolism, Development of Circulating Anticoagulants, Hemophilia, Von Willebrand\'s Disease, and Others), Type [Clinical Laboratory Analyzers (Controls & Calibrators, Assays & Reagents, Instruments/Systems, Coagulation Factors, and Others) and Point-of-Care Testing Analyzers], Offering [Diagnosis (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimmer Testing, Platelets Function Testing, and Others) and Treatment (Anti-Fibrinolytic Drugs, Birth Control Pills, Desmopressin & Immunosuppressive Medicines, Vitamin K Supplements, Blood Thinners, Thrombin Inhibitors or Thrombolytics, Replacement Therapy, Catheter-Assisted Thrombus Removal, and Others)], Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Others), and End User (Clinical Laboratories, Hospitals, and Others)


No. of Pages: 116    |    Report Code: BMIRE00029855    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Europe Coagulation Market

The Europe coagulation market was valued at US$ 2,000.64 million in 2022 and is expected to reach US$ 3,379.71 million by 2030; it is estimated to grow at a CAGR of 6.8% from 2022 to 2030.



Rising Prevalence of Cardiovascular Diseases Fuel Europe Coagulation Market

Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.

A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.

Europe Coagulation Market Overview

The Europe coagulation market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe holds a significant position in the global coagulation market and is estimated to register a robust CAGR during 2022-2030. Market growth in this region is mainly attributed to the rising incidence of cardiovascular disorders, increasing advancements in medical devices, the growing aging population, and the surging awareness of coagulation analyzers.

A large number of people in Germany are suffering from cardiovascular disorders, which can be attributed to the growing aging population in the country. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million of the German population have been diagnosed with CHD till date, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, the count of deaths caused by CHD in Germany reached 147,055 (i.e., 20.98% of total deaths).

Europe Coagulation Market Revenue and Forecast to 2030 (US$ Million)

Europe Coagulation Market Segmentation

The Europe coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Europe coagulation market share in 2022.

Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Europe coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Europe coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Europe coagulation market share in 2022.

By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Europe coagulation market share in 2022.

Based on country, the Europe coagulation market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation market in 2022.

F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB are some of the leading companies operating in the Europe coagulation market.


Europe Coagulation Strategic Insights

Strategic insights for the Europe Coagulation provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/europe-coagulation-market-strategic-framework.webp
Get more information on this report

Europe Coagulation Report Scope

Report Attribute Details
Market size in 2022 US$ 2,000.64 Million
Market Size by 2030 US$ 3,379.71 Million
Global CAGR (2022 - 2030) 6.8%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Disease Indications
  • Vitamin K Deficiency
  • Liver Disease
  • Disseminated Intravascular Coagulation & Pulmonary Embolism
  • Development of Circulating Anticoagulants
  • Hemophilia
  • Von Willebrand's Disease
By Type
  • Clinical Laboratory Analyzers
  • Point-of-Care Testing Analyzers
By Offering
  • Prothrombin Time Testing
  • Fibrinogen Testing
  • Activated Clotting Time Testing
  • Activated Partial Thromboplastin Time Testing
  • D-Dimmer Testing
  • Platelets Function Testing
By Treatment
  • Anti-Fibrinolytic Drugs
  • Birth Control Pills
  • Desmopressin & Immunosuppressive Medicines
  • Vitamin K Supplements
  • Blood Thinners
  • Thrombin Inhibitors or Thrombolytics
  • Replacement Therapy
  • Catheter-Assisted Thrombus Removal
By Technology
  • Optical Technology
  • Mechanical Technology
  • Electrochemical Technology
Regions and Countries Covered Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Market leaders and key company profiles
  • F. Hoffmann-La Roche Ltd
  • Genrui Biotech Co., Ltd
  • Horiba Ltd.
  • ImproGen Diagnostik Kimya San. & Tic. Ltd.ti
  • Nordic Biomarker AB
  • Siemens Healthineers AG
  • Sysmex Corp
  • Transasia Bio-Medicals Ltd
  • Get more information on this report

    Europe Coagulation Regional Insights

    The geographic scope of the Europe Coagulation refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/europe-coagulation-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Coagulation Market

    1. F. Hoffmann-La Roche Ltd

    2. Genrui Biotech Co., Ltd

    3. Horiba Ltd.

    4. ImproGen Diagnostik Kimya San. & Tic. Ltd.?ti

    5. Nordic Biomarker AB

    6. Siemens Healthineers AG

    7. Sysmex Corp

    8. Transasia Bio-Medicals Ltd

     

     

    Frequently Asked Questions
    How big is the Europe Coagulation Market?

    The Europe Coagulation Market is valued at US$ 2,000.64 Million in 2022, it is projected to reach US$ 3,379.71 Million by 2030.

    What is the CAGR for Europe Coagulation Market by (2022 - 2030)?

    As per our report Europe Coagulation Market, the market size is valued at US$ 2,000.64 Million in 2022, projecting it to reach US$ 3,379.71 Million by 2030. This translates to a CAGR of approximately 6.8% during the forecast period.

    What segments are covered in this report?

    The Europe Coagulation Market report typically cover these key segments-

    • Disease Indications (Vitamin K Deficiency, Liver Disease, Disseminated Intravascular Coagulation & Pulmonary Embolism, Development of Circulating Anticoagulants, Hemophilia, Von Willebrand\'s Disease)
    • Type (Clinical Laboratory Analyzers, Point-of-Care Testing Analyzers)
    • Offering (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimmer Testing, Platelets Function Testing)
    • Treatment (Anti-Fibrinolytic Drugs, Birth Control Pills, Desmopressin & Immunosuppressive Medicines, Vitamin K Supplements, Blood Thinners, Thrombin Inhibitors or Thrombolytics, Replacement Therapy, Catheter-Assisted Thrombus Removal)
    • Technology (Optical Technology, Mechanical Technology, Electrochemical Technology)

    What is the historic period, base year, and forecast period taken for Europe Coagulation Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Coagulation Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Coagulation Market?

    The Europe Coagulation Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • F. Hoffmann-La Roche Ltd
  • Genrui Biotech Co., Ltd
  • Horiba Ltd.
  • ImproGen Diagnostik Kimya San. & Tic. Ltd.ti
  • Nordic Biomarker AB
  • Siemens Healthineers AG
  • Sysmex Corp
  • Transasia Bio-Medicals Ltd
  • Who should buy this report?

    The Europe Coagulation Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Coagulation Market value chain can benefit from the information contained in a comprehensive market report.